Other

Kypha, Inc.

Potentia Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Oldenburg Group, Inc.

Uop Lcc

Milwaukee Sign Co., L.l.c.

Mitsubishi Chemical Composites America, Inc.

Paul Olson

Cedric Francois

Pascal Deschatelets

Donald W Olson

Don W Moss

Eric D Olson

Nicholas Staten

Michael A Arndt

Susie C Martins

Avram Michael Buchbinder

Douglas A Nafis

Kaitlin M DeSalvo

Jimalee Rae Beno

William Yannetti

Alec Machiels

Robert D Funk

Zhouning Zhang

Michael R McNamara

Jimalee R Beno

James Moses

Alfred Kim

Michael Bowie

Michael Brendel

Donald W Moss

Nick Staten

Donald Moss

Automated bag forming systems and methods for their use are disclosed. The automated bag forming systems described herein can be configured to receive a web of bag material and produce individual bags through a sealing and cutting process possessing a high degree of speed, precision, and reproducibility.

Automated bag former

A counter-pressure filler system includes a vertically-translatable platform capable of supporting a container, a pressurizable chamber having an entrance aperture, the chamber enclosing a seaming chuck and at least one seaming roller, a vertically-translatable enclosure comprising an upper portion configured to engage a portion of said chamber around the entrance aperture, thereby creating a pressurizable atmosphere within said vertically-translatable enclosure and the pressurizable chamber. The seaming chuck is configured to allow a beverage ingredient to pass therethrough and into said container.

Counter-pressure filler

A composite panel structure of a polymer matrix core sandwiched by metal layers is described. The polymer matrix comprises 1-30 wt % fluoropolymer and 70-99 wt % of a flame retardant mineral. The fluoropolymer may be polyvinylidene fluoride (PVDF) with a high limiting oxygen index, which confers fire resistance properties to the polymer matrix and the composite panel structure. The composite panel structure may be used on the exterior of buildings and may fulfill building code requirements for the polymer matrix core being noncombustible as determined by ASTM E136 and CAN/ULC S114 compliance.

Composite panel having noncombustible polymer matrix core

In some embodiments, the present invention provides methods for treating pregnant patients at risk of adverse pregnancy outcome, including, in some embodiments, by measuring one or more of a level of iC3b, intact C3, and total C3.

Methods for predicting and treating patients with increased risk of adverse pregnancy outcome

A method for forming a food package product is disclosed. The food package product includes layers and patches of adhesive strategically placed on packaging stock that prevents leakage of liquid products. In an exemplary embodiment, the food package product is microwavable popcorn.

Leak-resistant food package products and methods therefor

A food packaging system includes, in a serially coupled, operational configuration: a) an automated bag forming system; b) a bag rotator; c) a blade wheel; d) a bag top opener assembly; e) a funnel positioning system; f) a hopper system; g) an oil injection system; h) a sealing station; i) a crimping assembly; and j) an offloading assembly. A carriage conveyor system is configured to receive a bag formed by the automated bag forming system and convey the bag sequentially from component b) to component j).

Systems and methods for automated food packaging

The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

Methods of selecting compstatin mimetics

A method for treating an individual at risk for a complement-associated disorder is provided, the method including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays for the qualitative and quantitative point-of-care detection of complement activation and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein.

Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

A method for regenerating deactivated acidic ionic liquid is described. The method involves reducing a level of free hydrochloric acid in the deactivated acidic ionic liquid in a removal zone using at least one of heat, a stripping fluid, reduced pressure, and liquid-liquid extraction to form a deactivated acidic ionic liquid having a reduced level of free hydrochloric acid; and regenerating the deactivated acidic ionic liquid having the reduced level of free hydrochloric acid.

Hydrochloric acid stripping process for ionic liquid regeneration process

The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.

Complement assays and uses thereof

A method for treating an individual at risk for a complement-associated disorder is provided, including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein.

Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.

Growing community of inventors

Louisville, KY, United States of America

Paul Olson